{
    "doi": "https://doi.org/10.1182/blood.V122.21.5544.5544",
    "article_title": "Use Of Unrelated Donors In Elderly Patients (age >60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies ",
    "article_date": "November 15, 2013",
    "session_type": "731. Clinical Allogeneic and Autologous Transplantation - Results",
    "abstract_text": "Objectives The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in older patients. However, there are only limited data on the feasibility and outcomes of URD HCT in elderly patients.The aim of the study was to compare the outcome in OS and PFS for patients transplanted using unrelated donor (URD) in patients age 60 or older. Patients and methods We retrospectively analyzed outcomes in 62 consecutive hematologic malignancy patients aged > or =60 years (median, 62 years; range: 60-70 years) undergoing reduced intensity conditioning regimens (RIC) from URD. In this study, URD was used only when a MRD was not available. Then we compared the outcome of 17 elderly patients (age >65 years) with 44 younger patients aged between 60 and 65 years. Patient, disease and transplant characteristics are shown in Table 1 . Table 1 Study population characteristics  . All patients (n=61) . Age>60<65 (n=44) . Age=>65 (n=17) . P value . . n . % . n . % . n . % . Age         Median [range] 62 [60-70] 62 [60-64] 66 [65-70] <0.001 Diagnosis        0.314 Acute leukemia/MDS 38 62 25 57 13 76 Lymphoma/CLL 12 20 11 25 1 6 Multiple Myeloma 4 7 2 5 2 12 Myelofibrosis 5 8 5 11 0 0 CML 1 2 1 2 0 0 Aplastic anemia 1 2 0 0 1 6 Disease risk index        0.216 Low 9 15 8 18 1 6 Intermediate 38 63 25 57 13 77 High 13 22 11 25 2 12 Very High 0 0 0 0 0 0 HLA compatibility        0.281 10/10 53 87 37 84 16 94 9/10 8 13 7 16 1 6 Graft source        0.632 PBSC 58 95 42 95 16 94 BM 3 5 2 5 1 6 Conditioning regimen        0.014 Flu-Bu 51 84 38 86 13 76 Flu-TBI 3 5 1 2 2 12 Other 7 11 5 11 2 12 ATG        0.062 Yes 57 93 43 98 14 82 No 4 7 1 2 3 18 GVHD prophylaxis         CsA 49 80 37 84 12 71 0.200 CsA + MMF 12 20 7 16 5 29  HCT-CI [DB1]       0.290 0-2 32 56 21 52 15 88 =>3 25 44 19 48 2 12 Unknown 4  4  0  Follow up        0.030 Median [range] 36 [5-74] 40 [7-74] 13 [5-66] . All patients (n=61) . Age>60<65 (n=44) . Age=>65 (n=17) . P value . . n . % . n . % . n . % . Age         Median [range] 62 [60-70] 62 [60-64] 66 [65-70] <0.001 Diagnosis        0.314 Acute leukemia/MDS 38 62 25 57 13 76 Lymphoma/CLL 12 20 11 25 1 6 Multiple Myeloma 4 7 2 5 2 12 Myelofibrosis 5 8 5 11 0 0 CML 1 2 1 2 0 0 Aplastic anemia 1 2 0 0 1 6 Disease risk index        0.216 Low 9 15 8 18 1 6 Intermediate 38 63 25 57 13 77 High 13 22 11 25 2 12 Very High 0 0 0 0 0 0 HLA compatibility        0.281 10/10 53 87 37 84 16 94 9/10 8 13 7 16 1 6 Graft source        0.632 PBSC 58 95 42 95 16 94 BM 3 5 2 5 1 6 Conditioning regimen        0.014 Flu-Bu 51 84 38 86 13 76 Flu-TBI 3 5 1 2 2 12 Other 7 11 5 11 2 12 ATG        0.062 Yes 57 93 43 98 14 82 No 4 7 1 2 3 18 GVHD prophylaxis         CsA 49 80 37 84 12 71 0.200 CsA + MMF 12 20 7 16 5 29  HCT-CI [DB1]       0.290 0-2 32 56 21 52 15 88 =>3 25 44 19 48 2 12 Unknown 4  4  0  Follow up        0.030 Median [range] 36 [5-74] 40 [7-74] 13 [5-66] Legend: MM, multiple myeloma; MDS, myelodysplastic syndrome; MF, myelofibrosis; CLL, chronic lymphocytic leukemia; PBSC, peripheral blood stem cells ; BM, bone marrow ; Flu, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; GVHD, graft versus host disease; CSA, cyclosporine A; MMF, mycophenolate mofetyl; HCT-CI, HCT comorbidity index score. View Large Results No patients experienced graft rejection. The median HCT comorbidity index score was 2 (range, 0 to 6). With a median follow up of 36 months (range, 5-74), the cumulative incidence of grades II to IV acute GVHD was 28% and of grades III to IV acute GVHD, 13%. At 2 years, the cumulative incidence of chronic GVHD was 27%, progression-free survival (PFS) was 62%, overall survival (OS) was 63%, and relapse was 14%. Non relapse mortality (NRM) was 24% at 2 years. The cumulative incidence of grade II\u2013IV Acute GVHD was 43% for the younger group and 17% for the older group (P = 0.056). The cumulative incidence of chronic GVHD was not different between the two groups (23% vs. 45% (p=0.3), respectively). Two-year OS and PFS was 57% versus 86% (P = 0.059) and 55% versus 86% (P = 0.03), in the younger and the older group respectively. The 2-year NRM and relapse was 26% versus 14% (P = 0.4) and 19% versus 0% (P = 0.04), in the younger and older group respectively. Conclusions This retrospective study suggest that RIC HCT from URD is a safe and effective option for patients aged > or =60 years or older, and in the absence of suitable related donors, well-matched URD may offer a very reasonable alternative, and that does not appear to be associated with a detrimental outcome. However these results are encouraging showing once again that with an adequate selection, age is not a definitive limitation. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "conditioning (psychology)",
        "donors",
        "hematologic neoplasms",
        "hematopoietic stem cell transplantation",
        "older adult",
        "cyclosporine",
        "graft-versus-host disease",
        "graft-versus-host disease, acute",
        "influenza",
        "follow-up"
    ],
    "author_names": [
        "El-Cheikh Jean",
        "Devillier Raynier",
        "F\u00fcrst Sabine",
        "Crocchiolo Roberto",
        "Granata Angela",
        "Faucher Catherine",
        "Mohty Bilal",
        "Harbi Samia",
        "Bouabdallah Reda",
        "Vey Norbert",
        "Castagna Luca",
        "Chabannon Christian",
        "Didier Blaise, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "El-Cheikh Jean",
            "author_affiliations": [
                "Unit\u00e9 de Transplantation et de Th\u00e9rapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Devillier Raynier",
            "author_affiliations": [
                "Institut Paoli-Calmettes, D\u00e9partement d'Onco-H\u00e9matologie, Marseille, France, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "F\u00fcrst Sabine",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Transplantation et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Crocchiolo Roberto",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Greffe et de Th\u00e9rapie Cellulaire (UT), Marseille, France, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Granata Angela",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Transplantation et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Faucher Catherine",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Greffe et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mohty Bilal",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Greffe et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Harbi Samia",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Greffe et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bouabdallah Reda",
            "author_affiliations": [
                "Institut Paoli-Calmettes, D\u00e9partement d'Onco-H\u00e9matologie, Marseille, France, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vey Norbert",
            "author_affiliations": [
                "Institut Paoli-Calmettes, D\u00e9partement d'Onco-H\u00e9matologie, Marseille, France, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Castagna Luca",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Unit\u00e9 de Greffe et de Th\u00e9rapie Cellulaire (U2T), Marseille, France, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Chabannon Christian",
            "author_affiliations": [
                "Institut Paoli-Calmettes, Centre de Th\u00e9rapie Cellulaire, Marseille, France, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Didier Blaise, MD",
            "author_affiliations": [
                "Hematology department, Transplant Program, Institut Paoli Calmettes, Marseille, France"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T21:34:46",
    "is_scraped": "1"
}